NMN (nicotinamide mononucleotide) and healthy aging
What 2 graded rows on nmn (nicotinamide mononucleotide) agree on for healthy aging, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the NMN (nicotinamide mononucleotide) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the NMN (nicotinamide mononucleotide) page, with its PubMed record.
Your question
NMN (nicotinamide mononucleotide) and healthy aging
2 rows · 492 peopleThey agree: both rows found an improvement.
- CGrade C× 2
- Rows
- 2
- Trials
- 2
- At least: a review without a trial count
- People
- 492
- Pooled reviews may count some twice
What the rows share
From the rowsThe best-graded row, grade C, is a meta-analysis of 412 people (2025) and found an improvement.
The rows run from 80 to 412 people, published from 2023 to 2025: 1 pooled review and 1 single study.
The rows
2 improved- CGrade CGait speed and liver enzymes in middle-aged and older adults · Improved
Meta-analysis · n 412 · 2025 · Middle-aged and older adults in 9 randomized controlled trials
Varied; small doses had the largest effect on HOMA-IR in subgroups · Varied across trials
NMN improved gait speed (SMD 0.34) and lowered ALT (SMD -0.29).
Row on the NMN (nicotinamide mononucleotide) page · PubMed 39185644 (opens PubMed)
- CGrade CBlood NAD and six-minute walking distance · Improved
RCT · n 80 · 2023 · Healthy middle-aged adults
300, 600 or 900 mg/day · 60 days
Blood NAD rose in all NMN groups versus placebo. Six-minute walking distance increased more with all doses than placebo, most with 600 and 900 mg. HOMA-IR did not differ from placebo, and NMN was well tolerated.
Row on the NMN (nicotinamide mononucleotide) page · PubMed 36482258 (opens PubMed)